вывод сеткой


Automated Impella® Controller

Acute heart failure and true cardiogenic shock, as its extreme degree, are the most dangerous complications of myocardial infarction. The cause of acute heart failure is a progressive decrease in the pump function of the ventricular myocardium due to the violation of coronary blood flow and oxygen supply.

  • The incidence of acute heart failure is an average of 1 per 10 000 population per year, with a mortality rate of 60-80%.
  • The only effective method of treatment is the fastest recovery of coronary blood flow (reperfusion) against the background of the use of effective auxiliary circulation.

Performing PTCA in complex coronary artery lesions (LCA trunk, multifocal lesion, etc.) in patients with multiple concomitant pathologies, including the presence of severe chronic heart failure, is a complex task, associated with a high risk of intraoperative and postoperative complications.

  • The use of the Impella auxiliary circulation system with the Impella 2.5 catheter pump in such cases can prevent hemodynamic destabilization associated with recurring episodes of reversible myocardial ischemia and a sharp decrease in blood pressure that occur with temporary occlusion of the coronary arteries with angioplasty instruments.

The assisted circulation technology of Impella is based on the direct catheterization of the cavities of the ventricles of the heart and the pumping of blood into the central vessels along the shortest (anatomical) pathway with the help of miniature axial blood pumps built into the cannula with an inlet and an outlet for blood.

This excludes the outer contour of the auxiliary circulation, consisting of cannulas, trojuses, filters and other components, requiring filling (priming) with the patient's blood, reducing BCC and provoking an immune-inflammatory response from the blood.

  • The design of Impella catheter pumps allows them to be installed within minutes through a puncture or incision of peripheral arteries in conditions of an angiographic room.
  • The use of the circulatory system Impella® does not require cardiosurgical support.
  • The use of the assisted circulation system of Impella® has a very low risk of thromboembolic, infectious complications and hemolysis.
  • The use of the assisted circulation system of Impella® suggests a simple and liberal regimen of anticoagulant therapy.
  • The Impella auxiliary circulation system with Impella catheter pumps provides direct hemodynamic discharge of the ventricular myocardium.

The effectiveness and safety of the system is proved by a number of clinical studies, including randomized ones.

Impella® controller with the function of controlling and controlling the blood flow rate provides fast and personalized circulatory support.
The world's smallest blood pumps provide blood flow at a speed of 2.5 to 5.0 liters per minute, now have a number of modifications to provide hemodynamic support.